Related Experiment Videos
[Aplastic anemia in carbamazepine therapy]
D C Betticher1, H P Wolfisberg, R Krapf
1Medizinische Universitätsklinik, Inselspital Bern.
Schweizerische Medizinische Wochenschrift
|April 20, 1991
Summary
Carbamazepine can cause severe aplastic anemia, a rare but serious side effect. This case highlights the need for careful monitoring of blood counts during and after carbamazepine treatment for potential hematological toxicity.
Area of Science:
- Hematology
- Pharmacology
- Toxicology
Background:
- Carbamazepine is an anticonvulsant and mood-stabilizing drug.
- Aplastic anemia is a rare but life-threatening condition characterized by bone marrow failure.
Observation:
- A patient developed moderate pancytopenia after 10 days of carbamazepine (600 mg/day).
- Three years later, upon re-challenge with carbamazepine (400 mg/day for 120 days), the patient developed severe, irreversible pancytopenia consistent with bone marrow aplasia.
Findings:
- Extensive investigations ruled out other causes of aplastic anemia.
- The clinical history and response strongly implicate carbamazepine as the etiological agent.
Implications:
- This case underscores the rare but severe risk of carbamazepine-induced aplastic anemia.
- Recommendations for routine blood monitoring are crucial for early detection of this potentially lethal hematological side effect.
- Further literature analysis is needed to better understand dose- and time-dependent risks.